JP2018514204A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018514204A5 JP2018514204A5 JP2017554350A JP2017554350A JP2018514204A5 JP 2018514204 A5 JP2018514204 A5 JP 2018514204A5 JP 2017554350 A JP2017554350 A JP 2017554350A JP 2017554350 A JP2017554350 A JP 2017554350A JP 2018514204 A5 JP2018514204 A5 JP 2018514204A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- cell
- car
- signaling domain
- intracellular signaling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1507368.7A GB201507368D0 (en) | 2015-04-30 | 2015-04-30 | Cell |
| GB1507368.7 | 2015-04-30 | ||
| PCT/GB2016/051235 WO2016174461A1 (en) | 2015-04-30 | 2016-04-29 | T cell which expresses a gamma-delta t cell receptor (tcr) and a chimeric antigen receptor (car) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018514204A JP2018514204A (ja) | 2018-06-07 |
| JP2018514204A5 true JP2018514204A5 (enExample) | 2019-06-06 |
| JP6986449B2 JP6986449B2 (ja) | 2021-12-22 |
Family
ID=53488907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017554350A Expired - Fee Related JP6986449B2 (ja) | 2015-04-30 | 2016-04-29 | ガンマデルタｔ細胞受容体（ｔｃｒ）とキメラ抗原受容体（ｃａｒ）とを発現するｔ細胞 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20180125890A1 (enExample) |
| EP (1) | EP3288567B1 (enExample) |
| JP (1) | JP6986449B2 (enExample) |
| KR (1) | KR20180020140A (enExample) |
| CN (1) | CN107771215A (enExample) |
| AU (1) | AU2016255611B2 (enExample) |
| BR (1) | BR112017023409A2 (enExample) |
| CA (1) | CA2982532C (enExample) |
| EA (1) | EA201792042A1 (enExample) |
| ES (1) | ES3018558T3 (enExample) |
| GB (1) | GB201507368D0 (enExample) |
| HK (1) | HK1252235A1 (enExample) |
| IL (1) | IL255186B (enExample) |
| SG (1) | SG11201708402UA (enExample) |
| WO (1) | WO2016174461A1 (enExample) |
| ZA (1) | ZA201706923B (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201505858VA (en) | 2013-01-28 | 2015-09-29 | St Jude Childrens Res Hospital | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| EP3805371A1 (en) | 2014-05-15 | 2021-04-14 | National University of Singapore | Modified natural killer cells and uses thereof |
| GB201506423D0 (en) | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| GB201507368D0 (en) | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
| AU2018240556B2 (en) * | 2017-03-24 | 2025-02-27 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-CD33 immunotherapy |
| MX2019011570A (es) | 2017-03-27 | 2019-11-18 | Nat Univ Singapore | Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales. |
| CN117363636A (zh) | 2017-03-27 | 2024-01-09 | 新加坡国立大学 | 一种编码嵌合受体的多核苷酸 |
| WO2019025800A1 (en) * | 2017-08-02 | 2019-02-07 | Autolus Limited | CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE |
| CN111263640A (zh) | 2017-09-27 | 2020-06-09 | 俄亥俄州创新基金会 | 组织因子靶向car-nk和car-t细胞疗法 |
| GB201715918D0 (en) * | 2017-09-29 | 2017-11-15 | Tc Biopharm Ltd | Modified CAR-T |
| GB201720949D0 (en) | 2017-12-15 | 2018-01-31 | Autolus Ltd | Cell |
| JP7360174B2 (ja) | 2018-02-09 | 2023-10-12 | ナショナル ユニヴァーシティー オブ シンガポール | ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用 |
| GB201804701D0 (en) * | 2018-03-23 | 2018-05-09 | Gammadelta Therapeutics Ltd | Lymphocytes expressing heterologous targeting constructs |
| US12441787B2 (en) | 2018-04-02 | 2025-10-14 | National University Of Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| WO2019192526A1 (zh) * | 2018-04-04 | 2019-10-10 | 达仁生物科技有限公司 | 嵌合抗原受体和其治疗癌症的方法 |
| US12227756B2 (en) * | 2018-04-18 | 2025-02-18 | Ucl Business Ltd | Engineered regulatory T cell |
| CN108588023B (zh) | 2018-05-09 | 2020-02-14 | 河北森朗生物科技有限公司 | 一种生产嵌合抗原受体修饰的γδT细胞的方法 |
| CN110577932A (zh) * | 2018-06-07 | 2019-12-17 | 亘喜生物科技（上海）有限公司 | 一种脐带血来源的嵌合抗原受体t细胞 |
| WO2019242632A1 (en) * | 2018-06-19 | 2019-12-26 | 1§1Nanjing Legend Biotech Co., Ltd. | Engineered cells and uses thereof |
| CN112368298A (zh) * | 2018-06-22 | 2021-02-12 | 凯德药业股份有限公司 | 嵌合跨膜蛋白及其用途 |
| WO2020027094A1 (ja) | 2018-07-31 | 2020-02-06 | サイアス株式会社 | ｉＰＳ細胞を介して再生Ｔ細胞集団を製造する方法 |
| WO2020033464A1 (en) * | 2018-08-07 | 2020-02-13 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Car t-cells for the treatment of bone metastatic cancer |
| US12569507B2 (en) | 2018-08-07 | 2026-03-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | CAR T-cells for the treatment of bone metastatic cancer |
| JP7382603B2 (ja) * | 2018-08-10 | 2023-11-17 | 国立大学法人京都大学 | Ｃｄ３陽性細胞の製造方法 |
| WO2020044239A1 (en) | 2018-08-29 | 2020-03-05 | National University Of Singapore | A method to specifically stimulate survival and expansion of genetically-modified immune cells |
| JP7457007B2 (ja) * | 2018-09-19 | 2024-03-27 | ラヴァ・セラピューティクス・エヌ・ヴイ | 二重作用ＣＤ１ｄ免疫グロブリン |
| CN109234236A (zh) * | 2018-09-29 | 2019-01-18 | 吉林大学第医院 | 一种嵌合抗原受体γδT细胞的制备方法 |
| US12698340B2 (en) * | 2018-10-01 | 2026-08-04 | Adicet Therapeutics, Inc. | Compositions and methods regarding engineered and non-engineered γδ T-cells for treatment of solid tumors |
| BR112021006182A2 (pt) * | 2018-10-01 | 2021-06-29 | Adicet Bio, Inc. | composições e métodos relativos a células t¿d,d engenheiradas e não engenheiradas para tratamento de tumores hematológicos |
| CN113226340A (zh) | 2018-11-26 | 2021-08-06 | 恩卡尔塔公司 | 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途 |
| WO2020156335A1 (zh) | 2019-01-29 | 2020-08-06 | 上海交通大学 | 一种嵌合抗原受体及其应用 |
| US20220088074A1 (en) * | 2019-02-21 | 2022-03-24 | Regents Of The University Of Minnesota | Genetically modified gamma delta t cells and methods of making and using |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| BR112021017046A2 (pt) * | 2019-04-12 | 2021-11-09 | Phanes Therapeutics Inc | Receptores de antígeno quiméricos antirreceptores de folato 1 humanizados e seus usos |
| EP3959307A4 (en) * | 2019-04-22 | 2023-08-23 | Nanjing Legend Biotech Co., Ltd. | Engineered cells and uses thereof |
| CN113939302A (zh) | 2019-06-14 | 2022-01-14 | 赛雅思株式会社 | 医药组合物 |
| US20220259281A1 (en) * | 2019-06-21 | 2022-08-18 | Shattuck Labs, Inc. | Chimeric protein expressing t-cells |
| GB201909283D0 (en) * | 2019-06-27 | 2019-08-14 | Cancer Research Tech Ltd | Fusion proteins with enzyme activity |
| GB201915359D0 (en) | 2019-10-23 | 2019-12-04 | Ucl Business Ltd | Engineered regulatory t cell |
| AU2020370033A1 (en) | 2019-10-23 | 2022-06-02 | Ucl Business Ltd | Engineered regulatory T cell |
| CN110981972B (zh) * | 2019-12-25 | 2022-09-30 | 华夏源（上海）细胞基因工程股份有限公司 | 一种分泌双特异性抗体的嵌合抗原受体及其表达载体和应用 |
| GB202002581D0 (en) * | 2020-02-24 | 2020-04-08 | Gammadelta Therapeutics Ltd | Novel antibodies |
| CR20220431A (es) * | 2020-03-03 | 2023-02-21 | Janssen Biotech Inc | CÉLULAS T yo Y USOS DE ESTAS |
| CN117843812A (zh) | 2020-05-22 | 2024-04-09 | 重庆精准生物技术有限公司 | 逆转肿瘤微环境的融合蛋白及其应用 |
| CN116348485A (zh) | 2020-07-17 | 2023-06-27 | 英研生物(英国)有限公司 | 提供用于过继性细胞疗法的靶向共刺激的受体 |
| US12012441B2 (en) | 2020-10-26 | 2024-06-18 | Neptune Biosciences Llc | Engineered human IL-21 cytokines and methods for using the same |
| TW202306997A (zh) | 2021-06-16 | 2023-02-16 | 英商英斯特生物科技有限公司 | 用於在過繼細胞療法中提供標靶共刺激之受體 |
| EP4370213A4 (en) | 2021-07-16 | 2025-06-04 | Instil Bio (Uk) Limited | Chimeric molecules for targeted costimulation for adoptive cell therapy |
| CN113528455A (zh) * | 2021-07-19 | 2021-10-22 | 广州百暨基因科技有限公司 | 表达嵌合抗原受体的γδT细胞 |
| WO2023060126A1 (en) * | 2021-10-06 | 2023-04-13 | Dana-Farber Cancer Institute, Inc. | Engineered cytokine receptors for tunable adoptive cell therapy |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1147186A4 (en) | 1999-01-28 | 2002-05-15 | Palmetto Health Alliance D B A | In vitro activated gamma delta lymphocytes |
| ES2336302T3 (es) | 2000-04-03 | 2010-04-12 | Therapure Biopharma Inc. | Produccion de celulas ttcr gamma delta. |
| BRPI0113757B8 (pt) | 2000-09-11 | 2017-11-07 | Chiron Corp | derivados de quinolinona como inibidores de tirosina quinase |
| WO2006006720A1 (ja) | 2004-07-13 | 2006-01-19 | Medinet., Co.Ltd | γδＴ細胞の培養方法、γδＴ細胞及び治療・予防剤 |
| ATE476497T1 (de) | 2004-08-19 | 2010-08-15 | Univ Cardiff | Präparation antigenpräsentierender menschlicher gamma delta t-zellen und verwendung in der immuntherapie |
| JPWO2008152822A1 (ja) | 2007-06-15 | 2010-08-26 | 株式会社メディネット | 医薬 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US9833476B2 (en) * | 2011-08-31 | 2017-12-05 | The Trustees Of Dartmouth College | NKP30 receptor targeted therapeutics |
| EP2814846B1 (en) * | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| WO2013174404A1 (en) * | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| US10117896B2 (en) * | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| SG11201507026WA (en) | 2013-02-06 | 2015-10-29 | Anthrogenesis Corp | Modified t lymphocytes having improved specificity |
| SG11201505896YA (en) * | 2013-02-20 | 2015-09-29 | Novartis Ag | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| UY35468A (es) * | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| EP2997134B1 (en) * | 2013-05-14 | 2020-06-24 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| EP3027204B1 (en) * | 2013-07-29 | 2022-01-05 | 2seventy bio, Inc. | Multipartite signaling proteins and uses thereof |
| US9907820B2 (en) | 2013-10-25 | 2018-03-06 | Board Of Regents, The University Of Texas System | Polyclonal gamma delta T cells for immunotherapy |
| WO2015066262A1 (en) * | 2013-11-04 | 2015-05-07 | Trustees Of Dartmouth College | Methods for preventing toxicity of adoptive cell therapy |
| EP3858379A1 (en) * | 2013-11-21 | 2021-08-04 | Autolus Limited | Cell |
| DK3105335T3 (da) | 2014-02-14 | 2020-01-13 | Univ Texas | Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf |
| GB201403972D0 (en) * | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
| CN122399016A (zh) | 2014-03-15 | 2026-07-17 | 诺华股份有限公司 | 使用嵌合抗原受体治疗癌症 |
| US20170158749A1 (en) * | 2014-04-23 | 2017-06-08 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) and methods for making and using the same |
| WO2016005752A1 (en) | 2014-07-09 | 2016-01-14 | Tc Biopharm Ltd | Gamma delta t cells and uses thereof |
| GB201506423D0 (en) | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| RU2756247C2 (ru) | 2014-11-17 | 2021-09-28 | Эдисет Био, Инк. | Генетически модифицированные гамма дельта т-клетки |
| GB201507368D0 (en) | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
| CN105158466B (zh) | 2015-05-05 | 2017-12-22 | 中国科学院广州生物医药与健康研究院 | 一种检测抗cd19的嵌合抗原受体t细胞对白血病细胞抑制作用的方法 |
-
2015
- 2015-04-30 GB GBGB1507368.7A patent/GB201507368D0/en not_active Ceased
-
2016
- 2016-04-29 KR KR1020177034648A patent/KR20180020140A/ko not_active Ceased
- 2016-04-29 CA CA2982532A patent/CA2982532C/en active Active
- 2016-04-29 AU AU2016255611A patent/AU2016255611B2/en active Active
- 2016-04-29 BR BR112017023409-2A patent/BR112017023409A2/en not_active IP Right Cessation
- 2016-04-29 EP EP16720532.7A patent/EP3288567B1/en active Active
- 2016-04-29 US US15/567,165 patent/US20180125890A1/en not_active Abandoned
- 2016-04-29 ES ES16720532T patent/ES3018558T3/es active Active
- 2016-04-29 HK HK18111473.3A patent/HK1252235A1/zh unknown
- 2016-04-29 JP JP2017554350A patent/JP6986449B2/ja not_active Expired - Fee Related
- 2016-04-29 CN CN201680024237.0A patent/CN107771215A/zh active Pending
- 2016-04-29 WO PCT/GB2016/051235 patent/WO2016174461A1/en not_active Ceased
- 2016-04-29 EA EA201792042A patent/EA201792042A1/ru unknown
- 2016-04-29 SG SG11201708402UA patent/SG11201708402UA/en unknown
-
2017
- 2017-10-12 ZA ZA2017/06923A patent/ZA201706923B/en unknown
- 2017-10-22 IL IL255186A patent/IL255186B/en unknown
-
2021
- 2021-11-17 US US17/528,836 patent/US12331316B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7340638B2 (ja) | Ｍｈｃ－ｅ拘束性エピトープ、結合分子ならびに関連する方法および使用 | |
| Lee et al. | Human γδ T cell subsets and their clinical applications for cancer immunotherapy | |
| Liu et al. | Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV | |
| JP6987134B2 (ja) | ペプチドエピトープを同定する方法、そのようなエピトープに結合する分子および関連用途 | |
| JP7146397B2 (ja) | 改変γδＴ細胞 | |
| Barrow et al. | Exploiting NK cell surveillance pathways for cancer therapy | |
| Seddiki et al. | Human antigen‐specific CD4+ CD25+ CD134+ CD39+ T cells are enriched for regulatory T cells and comprise a substantial proportion of recall responses | |
| JP2020058380A (ja) | キメラ抗原受容体及びその製造方法 | |
| BR112021002390A2 (pt) | processos para gerar células modificadas e suas composições | |
| JP2022541181A (ja) | Ｔｃｒ遺伝子の単離方法 | |
| JP2018532407A5 (enExample) | ||
| JP2017515464A5 (enExample) | ||
| JP2016538855A5 (enExample) | ||
| RU2022102250A (ru) | Клетка | |
| JP2016525873A (ja) | Ｔ細胞バランス遺伝子発現、組成物およびその使用方法 | |
| JP2018517410A5 (enExample) | ||
| CN107206024A (zh) | 改变cart细胞中的基因表达及其用途 | |
| EP4458419A3 (en) | Methods for expanding antigen-specific car-t cells, compositions and uses related thereto | |
| JP2017535292A5 (enExample) | ||
| Cutmore et al. | Current perspectives on the use of off the shelf CAR-T/NK cells for the treatment of cancer | |
| US20250154222A1 (en) | Techniques for generating cell-based therapeutics using recombinant t cell receptor genes | |
| Lu et al. | Hijacking TYRO3 from tumor cells via trogocytosis enhances NK-cell effector functions and proliferation | |
| Michen et al. | Artificial feeder cells expressing ligands for killer cell immunoglobulin-like receptors and CD94/NKG2A for expansion of functional primary natural killer cells with tolerance to self | |
| Chauhan et al. | Harnessing NK cell checkpoint-modulating immunotherapies | |
| WO2025213573A1 (zh) | 细胞免疫疗法的组合物和方法 |